Randomized Study in Children and Adolescents With Migraine: Acute Treatment
← catalyst calendarNCT04649242 · readout in 873 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
2,100estimated
Sites
245
Countries
Canada, China, Japan +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-15 | actual | When the study began enrolling |
| Primary completion | 2029-01-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-09 | estimated | The whole study's end, after follow-up |
| First posted | 2020-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pediatric Migraine
Interventions
- Drug: Rimegepant/BHV3000
- Drug: Matching placebo
Primary outcome
what the primary-completion date above is the date OFTo evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine in adolescent population (≥ 12 to <18 years of age) as measured by pain freedom using the number of patients reporting no pain.
measured 2 hours post-dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed